Seeking Alpha Reiterates Sell on Milestone as Losses Compound

What happened

Seeking Alpha reiterated a 'Sell' on Milestone Pharmaceuticals, citing weak differentiation for CARDAMYST and poor commercial uptake versus low-cost generics. The article highlighted that Q2 revenue was just $559K on over 1,200 scripts, reflecting heavy discounting and minimal payer coverage with only ~20% of the PSVT market covered. Financially, the company is deteriorating with $170M in cash, $39M burn in the first half, liabilities doubled to $163M, and equity falling to $18M amid high SG&A and compounding royalty debt. These points align with the DeepValue report's concerns that script growth has not translated into clean monetization despite strong prescriber and patient metrics. However, the DeepValue report also notes that commercial coverage improved to approximately 50% after quarter-end following UnitedHealthcare and other payer additions, which could be a positive catalyst if it converts to revenue.

Implication

The weak Q2 revenue despite script growth confirms that gross-to-net deductions are severe, and payer coverage remains insufficient to drive clean economics. With only $170M cash and a $39M burn in 1H, the runway extends into 2H27 but leaves little room for error, especially with royalty debt and potential ATM dilution. The stock trades near $1.27, close to the DeepValue bear case of $0.90, suggesting limited downside but also limited upside without a fundamental change. Investors should watch for Q4 revenue above $2M and coverage above 60% as triggers for re-evaluation. Until then, the risk/reward is unfavorable for new positions.

Thesis delta

The bear case has gained weight as weak revenue and high burn make the stock vulnerable to further declines. The DeepValue WAIT rating remains appropriate, but the deterioration in equity and rising liabilities reduce margin of safety. Upside now hinges on a sharp improvement in net revenue per script and no ATM usage.